Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.
City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.
